Product
SARS-CoV-2 rS/Matrix-M Adjuvant
Aliases
NVX-CoV2373
1 clinical trial
1 indication
Indication
COVID-19Clinical trial
A 2-Part, Phase 1/2, Randomized, Observer-Blinded Study To Evaluate The Safety And Immunogenicity Of A SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine (SARS-CoV-2 rS) With Or Without MATRIX-M™ Adjuvant In Healthy SubjectsStatus: Completed, Estimated PCD: 2022-06-01